149 related articles for article (PubMed ID: 23450486)
21. Immunophenotypic and genetic characteristics of diffuse large B-cell lymphoma in Taiwan.
Chang ST; Chen SW; Ho CH; Kuo CC; Sakata S; Takeuchi K; Chuang SS
J Formos Med Assoc; 2016 Nov; 115(11):961-967. PubMed ID: 27773559
[TBL] [Abstract][Full Text] [Related]
22. Diffuse Large B-Cell Lymphoma in Kenya: MYC, BCL2, and the Cell of Origin.
Wawire J; Sayed S; Moloo Z; Sohani AR
J Glob Oncol; 2019 May; 5():1-8. PubMed ID: 31045473
[TBL] [Abstract][Full Text] [Related]
23. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
[TBL] [Abstract][Full Text] [Related]
24. [Mechanism and clinical significance of anti-apoptotic gene bcl-2 expression in diffuse large B-cell lymphoma].
Zeng LP; Wen YL; Ma Y; Wang GQ; Li Y; Wang J; Xu LL; Zhang XM
Zhonghua Bing Li Xue Za Zhi; 2011 Jun; 40(6):377-81. PubMed ID: 21914345
[TBL] [Abstract][Full Text] [Related]
25. [Relation of MiR-34a Expression in Diffuse Large B Cell Lymphoma with Clinical Prognosis].
Liu YP; Hu H; Xu F; Wen JJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):455-459. PubMed ID: 28446292
[TBL] [Abstract][Full Text] [Related]
26. p53 expression in large B-cell lymphomas with MYC extra copies and CD99 expression in large B-cell lymphomas in relation to MYC status.
Richardson AI; Zhang D; Woodroof J; Cui W
Hum Pathol; 2019 Apr; 86():21-31. PubMed ID: 30496802
[TBL] [Abstract][Full Text] [Related]
27. A super-SILAC based proteomics analysis of diffuse large B-cell lymphoma-NOS patient samples to identify new proteins that discriminate GCB and non-GCB lymphomas.
van der Meeren LE; Kluiver J; Rutgers B; Alsagoor Y; Kluin PM; van den Berg A; Visser L
PLoS One; 2019; 14(10):e0223260. PubMed ID: 31603917
[TBL] [Abstract][Full Text] [Related]
28. Impact of Double Expression of C-MYC/BCL2 Protein and Cell of Origin Subtypes on the Outcome among Patients with Diffuse Large B-Cell Lymphoma: a Single Asian Center Experience.
Teoh CS; Lee SY; Chiang SK; Chew TK; Goh AS
Asian Pac J Cancer Prev; 2018 May; 19(5):1229-1236. PubMed ID: 29801406
[TBL] [Abstract][Full Text] [Related]
29. [Expression of CD68, cyclin D1 and rearrangement of bcl-6 gene are adverse prognostic factors in diffuse large B-cell lymphoma].
Liang X; Wang J; Bai W; Sun R
Zhonghua Bing Li Xue Za Zhi; 2015 Aug; 44(8):559-64. PubMed ID: 26705179
[TBL] [Abstract][Full Text] [Related]
30. [Clinical significance of bcl-2 protein expression and classification algorithm in diffuse large B-cell lymphoma].
Li M; Liu CL; Wang XY; Xue XM; Gao ZF
Zhonghua Bing Li Xue Za Zhi; 2012 Dec; 41(12):813-7. PubMed ID: 23324229
[TBL] [Abstract][Full Text] [Related]
31. [Clinicopathologic significance of bcl-6 gene rearrangement and expression in three molecular subgroups of diffuse large B-cell lymphoma].
Xu FP; Liu YH; Luo XL; Zhuang HG; Li L; Luo DL; Xu J; Zhang F; Zhang MH; Du X; Li WY
Zhonghua Bing Li Xue Za Zhi; 2008 Jun; 37(6):371-6. PubMed ID: 19031715
[TBL] [Abstract][Full Text] [Related]
32. [Immunophenotypes and prognosis of diffuse large B-cell lymphoma: a study of 500 cases].
Luo DL; Liu YH; Zhuang HG; Li L; Xu FP; Zhang F; Luo XL; Xu J
Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):235-9. PubMed ID: 21615996
[TBL] [Abstract][Full Text] [Related]
33. [Survival of patients with primary central nervous system diffuse large B-cell lymphoma: impact of gene aberrations and protein overexpression of bcl-2 and C-MYC, and selection of chemotherapy regimens].
Yin WJ; Zhu X; Yang HY; Sun WY; Wu MJ
Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):32-38. PubMed ID: 29325248
[No Abstract] [Full Text] [Related]
34. miR expression in MYC-negative DLBCL/BL with partial trisomy 11 is similar to classical Burkitt lymphoma and different from diffuse large B-cell lymphoma.
Zajdel M; Rymkiewicz G; Chechlinska M; Blachnio K; Pienkowska-Grela B; Grygalewicz B; Goryca K; Cieslikowska M; Bystydzienski Z; Swoboda P; Walewski J; Siwicki JK
Tumour Biol; 2015 Jul; 36(7):5377-88. PubMed ID: 25677902
[TBL] [Abstract][Full Text] [Related]
35. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
[TBL] [Abstract][Full Text] [Related]
36. [Detection of t (14; 18) translocation and bcl-2 amplification in diffuse large B-cell lymphoma].
Jiang HY; Li HL; Hu H; He Y; Zhao T
Zhonghua Bing Li Xue Za Zhi; 2007 Feb; 36(2):84-9. PubMed ID: 17493380
[TBL] [Abstract][Full Text] [Related]
37. [Clinical Significance of P53, C-MYC and BCL-6 Abnormality in Patients with Diffuse Large B Cell Lymphoma].
Chai CG; Zhang JJ; Li N; Cao L; Zhang SY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):89-93. PubMed ID: 26913400
[TBL] [Abstract][Full Text] [Related]
38. A microRNA-mediated regulatory loop modulates NOTCH and MYC oncogenic signals in B- and T-cell malignancies.
Ortega M; Bhatnagar H; Lin AP; Wang L; Aster JC; Sill H; Aguiar RC
Leukemia; 2015 Apr; 29(4):968-76. PubMed ID: 25311243
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathological study of gene rearrangement and microRNA expression of primary central nervous system diffuse large B-cell lymphomas.
Zheng J; Xu J; Ma S; Sun X; Geng M; Wang L
Int J Clin Exp Pathol; 2013; 6(10):2048-55. PubMed ID: 24133582
[TBL] [Abstract][Full Text] [Related]
40. [Significance of BCL6, MYC, P53 genes abnormalities for the prognosis of diffuse large B-cell lymphoma].
Gao P; Li Q; Wang Z; Yan F; Lu C; Cao X
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2014 Oct; 31(5):628-31. PubMed ID: 25297597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
